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Abbreviations 
AFR, aerosol flow reactor; API, active pharmaceutical ingredient; ASES, aerosol solvent 
extraction system; AUC, area under the blood concentration; BSA, bovine serum albumin; CQA, 
critical quality attributes; Cmax, maximum plasma concentration; CSD, colloidal silicon dioxide; 
DCP, dibasic calcium phosphate anhydrous; DMA, dimethylacetamide; DPI, dry powder 
inhalers; DSC, differential scanning calorimetry; EPAS, evaporative precipitation into aqueous 
solution; Eq, equation; GAS, gas anti-solvent; HGAP, high gravity antisolvent precipitation; 
HGCP, high gravity controlled precipitation; HGRP, high gravity reactive precipitation; HIV, 
human immunodeficiency virus; HP-β-CD, 2-Hydroxypropyl-β-cyclodextrin; IV, intravenous; 
HPC, hydroxypropyl cellulose; HPH, high-pressure homogenization; ILC, inulin lauryl 
carbamate; IVIVC, in vitro in vivo correlation; MCC, microcrystalline cellulose; NSAID, 
nonsteroidal antiinflammatory drug; P-gp, P-glycoproteins; PLGA, poly(lactide-co-glycolide); 
PLM, polarized light microscope; PSD, particle size distribution; PVA, polyvinyl alcohol; PVP, 
polyvinylpyrrolidone; RPB, rotating packed bed; RESS, rapid expansion in supercritical fluid; 
SAS, supercritical anti-solvent; SCF, supercritical fluid; SLNs, solid lipid nanoparticles; SDS, 
sodium dodecyl sulphate; SEDS, solution-enhanced dispersion by supercritical fluids; SDC, 
sodium deoxycholate; SEM, scanning electron microscopy; SFL, spray freezing into liquid; SGF, 
simulated gastric fluid; SLS, sodium lauryl sulphate; TEM, transmission electron microscopy; 
TPGS, D‒α‒tocopherol polyethylene glycol succinate; TPP, tripolyphosphate; UWL, unstirred 
water layer; WGG, wheat germ agglutinin; XRPD, X‒ray powder diffraction. 
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Abstract 
The advances in the field of nanotechnology have revolutionized the field of delivery of poorly 
soluble active pharmaceutical ingredients (APIs). Nanosized formulations have been extensively 
investigated to achieve a rapid dissolution and therefore pharmacokinetic properties similar to 
those observed in solutions. The present review outlines the recent advances, promises and 
challenges of the engineering nanosized APIs. The principles, merits, demerits and applications 
of the current ‘bottom-up’ and ‘top-down’ technologies by which the state of the art nanosized 
APIs can be produced were described. Although the number of research reports on the 
nanoparticle engineering topic has been growing in the last decade, the challenge is to take 
numerous research outcomes and convert them into strategies for the development of marketable 
products. 
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1. Introduction 
Nanoparticles refer to solid colloidal three-dimensional particles in the size range from 1 to 1000 
nm [1]. Therapeutically, nanoparticles could be used as API carriers (vehicles) through 
dissolving, entrapping or adsorbing the API. Historically, nanoparticles have been developed for 
API delivery since the 1960s [2]. Commercially, the first approved product employing 
nanoparticle formulation was ABI-007 (Abraxane
®
; American BioScience Inc., Santa 
Monica, CA) [3]. Nanotechnologies have been employed for the treatment of several diseases 
such as cancer [4], tuberculosis [5,6], etc. Nanotechnologies have been used to improve the 
solubility of hydrophobic APIs by two main approaches. The first approach involves the 
production of nanocrystals using techniques based on down-up methods, top-down methods, or a 
combination of top-down and down-up methods. The second approach involves nanotechnology-
based API delivery dosage forms such as polymeric micelles, nanosuspensions and/or 
nanoemulsions [7]. 
2. Solubility of nanosized APIs 
APIs administered orally have to be in the solution state to be absorbed and consequently induce 
a therapeutic response. It is estimated that at least 40% of the newly identified APIs are low 
soluble materials [8], making the formulation of such compounds challenging in the 
pharmaceutical industry. Therefore, universal solubilization methods that can significantly 
improve the APIs’ bioavailability are still highly desirable. In the literature, many techniques 
were used to improve the solubility of poorly soluble APIs, such as complexing APIs with 
cyclodextrins [9], conjugation to dendrimers [10], salt formation of ionizable APIs [11], solid 
dispersions [12], and lipid-based API delivery systems such as microemulsions and liposomes 
[13]. Nevertheless, some of these techniques were unsuccessful and thus the molecules were 
abandoned during early stages of development, or the product being launched exhibited 
suboptimal properties, including the poor bioavailability, the lack of fed/fasted equivalence, the 
lack of optimal dosing and the presence of extra excipients that pose limitations with respect to 
dose escalation, and ultimately a poor patient compliance [14].  
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Nanosized APIs proved promising properties in all stages of the API development process. 
According to the Nernst–Brunner/Noyes–Whitney equation [15–17], increasing the saturation 
solubility of an API will increase its dissolution rate from the pharmaceutical dosage form. This 
is described in equation 1 (Eq. 1; [18]). 
  
   
 
  
 
    
  
 
   (Eq. 1), 
where dX/dt is the dissolution rate, Xd is the amount dissolved, A is the particle surface area, D 
is the diffusion coefficient, V is the volume of fluid available for dissolution, Cs is the saturation 
solubility and h is the thickness of the effective boundary layer. Based on the above equation, the 
decrease of particle size will increase the effective particle surface area (A), eventually leading to 
an enhanced dissolution rate and thus an increased API bioavailability [19]. The applicability of 
this theory has been verified by many researchers [20,21]. Additionally, according to the Prandtl 
equation (Eq. 2), the decrease in particle size achieved for nanosized APIs will lead to a decrease 
in the thickness of the effective boundary layer, ultimately resulting in an increased API 
dissolution rate [22].  
      
  
  
    (Eq. 2), 
where L is the length of the surface in the direction of flow, k is a constant, V is the relative 
velocity of the flowing liquid against a flat surface and hH is the thickness of the hydrodynamic 
boundary layer. 
Additionally to the enhanced dissolution rate explained above, nanosized APIs have increased 
saturation solubility compared to an unmilled product of the same API, as illustrated by 
Freundlich–Ostwald equation [23,24] (Eq. 3). 
       
 
   
    
 
  (Eq. 3), 
where Cs is the saturation solubility of the nanosized API, C∞ is the saturation solubility of an 
infinitely large API crystal, γ is the crystal-medium interfacial tension, M is the compound’s 
molecular weight, r is particle radius, ρ is density, R is a gas constant and T is the temperature.  
Based on the above equation, Cs is a function of the interfacial tension (γ) and therefore is a 
function of the interfacial energy G (G = σ·A). High energy surfaces are likely to be created on 
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the surface of the milled nanosized API particles compared to parent microsized particles. Such 
differences in the interfacial energy may contribute to differences in Cs between nanosized and 
microsized APIs [25]. For example, Ganta et al. [26] showed how the saturation solubility of 
Asulacrine has dramatically increased for milled preparations compared to un-milled 
preparations. The solubility increased with successive size-reduction steps and the highest 
solubility was achieved with a median particle size of 133 nm. 
3. Bioavailability of nanosized APIs 
The number of poorly water-soluble APIs is increasing and, therefore, new methods to enhance 
their dissolution rates are always warranted [27]. Nanosized API particles received much 
interested due to their high specific surface areas and, therefore, their marked enhanced 
dissolution rates and bioavailabilities [25,28–35]. Most nanosized API formulations contain a 
stabilizer (usually a surfactant), which is likely to increase the wettability of hydrophobic APIs 
leading to an increased dissolution rate [36]. 
In the literature, the efficiency of the oral delivery of poorly soluble APIs was improved using 
several nano-strategies such as nanosuspensions [37], nanoemulsions [38], nanocrystals [39], 
polymeric nanoparticles [40], solid lipid nanoparticles (SLNs) [41], nanosized APIs loaded in 
mesoporous matrices[42,43], etc. Stable amorphous nanoparticle APIs with enhanced 
bioavailability have also been prepared [44]. The advantages of mesoporous nanomatrix 
formulations over polymeric nanoparticles include the ordered nanoscale porosity, the 
opportunity to control the size and morphology, the high specific area, the good stability and the 
high API loading capacity [45–47]. 
APIs usually get absorbed maximally at the duodenal-jejunal area, thus if the dissolution of an 
API was not completed in this area then the bioavailability of this API will be seriously 
compromised. In contrast to large API particles, which cannot adequately be dissolved in a 
specific absorption window, nanosized API particles are rapidly dissolved during the transit 
through the gut, potentially leading to a maximal absorption and an improved bioavailability 
[48].  
It has also been hypothesized that the increased bioavailability of the nanosized APIs compared 
to the unmilled APIs could be attributed to the increased effective intestinal permeability (by 
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diffusion through the epithelial cell membrane) for nanosized APIs, attributable to the decrease 
in the thickness of the unstirred water layer (UWL, a layer of water that is adjacent to the 
mucous membrane of the intestinal wall), ultimately leading to an increased amount of API that 
reaches the systemic circulation [49]. 
Recently, there have been increased attention towards both biorelevant in vitro [50] and in silico 
[36] methods for predicting the performance of nanosuspensions. 
 For example, Juenemann et al [50] evaluated the ability of in vitro biorelevant dissolution 
methods to predict the in vivo performance of both nanosized fenofibrate and microsized 
fenofibrate. A good correlation was demonstrated between the predicted in vivo performance and 
the biorelevant vitro dissolution method under the assumption that there is a permeability 
restriction. Simulated profiles showed the rate-determining step for absorption to change 
from dissolution-controlled in the case of micronized formulations to at least partly 
permeability-limited in the case of nanosized formulations. Gastric emptying was however 
shown to be a rate-determining for the absorption of fenofibrate from both the microsized 
and the nanosized formulations. 
When developing a dissolution method for nanosuspensions, the redispersibility analysis of the 
simulated gastric fluid (SGF) should be conducted to provide an initial estimate of the potential 
bioperformance. Particle size distributions should be measured before and after the 
redispersibility. Care should be considered to ensure the separation between the dissolved and 
undissolved material [36]. Jinno et al. [51] used a mixing tank model to predict the dissolution 
rates of cilostazol suspensions prepared using different techniques (hammer-mill, jet-mill and the 
nanocrystal technology). Good correlations were established showing that the dissolution rate of 
cilostazol was increased with the reduction in particle size. Shono et al. [36] confirmed that the 
bioavailability of nanosuspensions is guided by several factors, i.e., the increase in dissolution 
rate, the increase in saturation solubility and the reduction in effective permeability. However, it 
should be kept in mind that taking all the foregoing factors into account simultaneously could be 
complicated. 
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4. Nanosized APIs in oral delivery systems 
Nanosuspensions can be processed into dry powder and subsequently shaped into solid oral 
dosage forms such as capsules and/or tablets. Two approaches are currently available to achieve 
this goal [52]. The first approach is a two-step process. Nanosuspensions are subjected to solvent 
removal. Then, the resultant powder is further mixed with a suitable excipient before tableting or 
capsule filling. For example, rutin nanocrystals were freeze-dried and then incorporated into 
tablets that have shown improved API dissolution rate in comparison to the marketed product 
[53]. The second approach involves the formation of granules by using the nanosuspension 
solvent as a granulation liquid or layering dispersion in the fluidized bed process. However, such 
formulations may exhibit irreversible aggregation that is likely to lead to decreased 
bioavailability. A dispersant is usually used to prevent such aggregation. A study by Rao et al  
[54] found that sugars alone (25‒250 %, w/w) were not effective to prevent aggregation of 
albendazole nanosuspensions. However, such aggregation was no longer observed when 12.5 % 
(w/w) hypromellose, or 2.5 % (w/w) carbopol, were additionally used. 
Many solvent removal techniques have been employed to solidify nanosuspensions, including 
freeze-drying, spray-drying, vacuum-drying, oven-drying and fluidized bed-drying, as 
summarized in Table 1. 
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Table 1. A summary of some drying techniques used to isolate nanosized APIs from nanosuspensions (the grades used of MCC, DCP, 
silica and ILC were Avicel
®
 PH101, Fujicalin
®
, Aerosil
®
200 and Inutec
®
SP1 respectively) (
*
the stabilizer prevents the nanoparticle 
aggregation within a colloidal dispersion before drying; 
**
the matrix former prevents nanoparticle aggregation within a solid phase 
following drying). 
Drying 
technique 
API Nanosizing method Stabilizer
*
 Matrix former
**
 Reference 
Freeze-
drying 
Rutin HPH SDS or Tween 80 … [53] 
Azithromycin HPH Pluronic F68, tween 
80 and lecithin 
… [55] 
Oridonin HPH Pluronic F68 and 
lecithin 
Mannitol [56] 
Ascorbyl palmitate HPH Tween 80 Trehalose [57] 
Danazol Media milling Mannitol PVP [58] 
Iitraconazole Media milling TPGS MCC [59] 
Naproxen Media milling HPC and arginine None [60] 
Cinnarizine, griseofulvin, 
indomethacin, itraconazole, loviride, 
mebendazole, naproxen, 
phenylbutazone and phenytoin. 
Media milling TPGS MCC [61] 
Lovastatin 
 
Sonoprecipitation PVP/Pluronic 
F68/hypromellose and 
SDC 
Mannitol and glucose [62] 
Spray-
drying 
Itraconazole Micropreciptation-
HPH 
Poloxamer 188 and 
SDC 
Mannitol [63] 
Fenofibrate Antisolvent 
precipitation 
SDS and 
hypromellose E3 
Lactose and Mannitol [64] 
Celecoxib Emulsion-diffusion PVP or SDS … [65] 
Cinnarizine, griseofulvin, 
indomethacin, itraconazole, loviride, 
mebendazole, naproxen, 
phenylbutazone and phenytoin. 
Media milling TPGS MCC, DCP, silica or ILC [66] 
Salbutamol sulphate HGCP … … [67] 
Vacuum- Itraconazole, sofalcone, fenofibrate, Media milling HPC Carrageenan and alginic [68] 
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drying cilostazol and naproxen. acid and gelatine  
Artemisinin Evaporative 
precipitation 
… … [69] 
Quercetin Evaporative 
precipitation or HPH 
Pluronic F68 and 
lecithin 
… [70] 
Cefixime Sonoprecipitation PVP … [71] 
Indomethacin Ink jetting 
nanosuspension 
L‒arginine and PVP … [72] 
Oven-drying 
Griseofulvin Media milling HPC and SDS α‒lactose‒monohydrate [73] 
Ketoconazole Medial milling Hypromellose, 
poloxamer, PVP and 
SLS 
α‒lactose‒monohydrate [74] 
Fluidized 
bed 
processing 
Naproxen Media milling TPGS and 
hypromellose 
Sucrose and corn starch [75] 
Cinnarizine Media milling TPGS and 
hypromellose 
Sucrose and corn starch [75] 
Azodicarbonamide Media milling SDS α‒lactose‒monohydrate [76] 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
11 
 
Freeze-drying has been applied immediately after mixing of an API dissolved in an organic 
solvent with an antisolvent solution [77]. Controlled crystallization during freeze-drying was 
employed to control the size of the nano-freeze-dried fenofibrate [78]. Badawi et al. [79] freeze-
dried a nanosuspension of itraconazole (a class II API) to prepare a solid dosage form. However, 
the produced itraconazole nanocrystals exhibited a high degree of aggregation and consequently 
a decreased dissolution rate. Such aggregation was reduced by using a dispersing agent 
containing Avicel PH 101
®
 and Aerosil 200
®
. More examples from the literature include the use 
of freeze-drying to isolate albendazole [54], azithromycin [55], danazol [58], itraconazole [59], 
naproxen [60], oridonin [56], griseofulvin, indomethacin, loviride, mebendazole, naproxen, 
phenytoin [61], cinnarizine and phenylbutazone [66] nanosized particles.  
Spray-drying has been increasingly used as a drying procedure of nanosuspensions produced by 
either bottom-up or top-down methods. For example, nanosized nifedipine prepared by high- 
pressure homogenization (HPH) were spray-dried to isolate a solid product. Naproxen 
nanosuspensions produced using media milling technology were converted into dry powder 
nanocrystals using vacuum-drying. Other examples include the use of vacuum-drying to isolate 
the solid product of itraconazole, sofalcone, fenofibrate, cilostazol, naproxen [68], artemisinin 
[69] and quercetin [70]. Oven-drying was used to isolate many nanosized API crystals such as 
CRS 74 (a new antiretroviral drug) [80], indomethacin [72], lovastatin [62] and cefixime [71]. 
Additionally, fluidized bed process was used to dry several nanosized APIs such as 
griseofulvin [73], ketoconazole [74], naproxen, cinnarizine [75] and azodicarbonamide [76]. 
Ibuprofen nanocrystals produced by melt emulsification were dried using fluidized bed process 
[34]. 
Regardless of the drying method applied, nanosuspensions could aggregate upon drying, leading 
to a decreased API bioavailability obtained from solid dosage forms [81]. For example, a 
decreased bioavailability was observed for Danazol
®
 capsules compared to a liquid 
nanosuspension preparation [82]. Spray-dried nanocrystals usually show a high degree of 
aggregation when processed into tablets, such aggregation was prohibited when itraconazole 
nanocrystals were dispersed using mannitol and sodium deoxycholate (SDC) [63]. Vacuum dried 
naproxen nanocrystals also exhibited a high degree of aggregation, such aggregation was 
presented using carrageenan, gelatin and alginic acid used at concentrations above 12.5%, 50% 
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and 25% respectively [68]. Oven dried itraconazole nanocrystals showed little aggregation and 
up to 60.4% dissolution rate after 10 min [68]. In general, the aggregation induced by drying 
may be avoided by using carefully selected excipient such as sodium lauryl sulphate (SLS), 
sodium docusate and rapidly hydrating agents (e.g., carbohydrate based excipients) [41]. 
Formulating nanosized APIs into an oral dosage form possesses many advantages. For example, 
utilizing a nanosized API in oral dosage forms will have an effect on the P-glycoproteins (P-gp). 
Many studies referred that the use of a stabilizer in nanosized formulations inhibits P-gp that is 
located in the apical membrane of the intestine [83]. However, all studies used in-situ methods 
such as the cacao cell culture everted gut sac and single pass perfusion with no in vitro in vivo 
correlation (IVIVC) been established [52].  
Hydrophobic APIs usually show significant variations in the absorption between the fed and fast 
states. The API dissolution might be enhanced in the fed state due to many factors such as the 
delayed gastric emptying, increased gastric pH, increased gastric volume, increased bile 
secretion and increased splanchnic blood flow. Nanosized delivery systems have also the merit 
of minimizing the fed/fast fluctuations observed with some formulations intended for oral drug 
delivery [84]. For example, commercial megestrol acetate formulation showed significant 
fluctuations in the maximum plasma concentration (Cmax) and area under the blood 
concentration–time curve (AUC) in the fed state as compared to fast-state; however, the 
nanosized formulations showed reduced fluctuations and improved oral bioavailabilities 
compared to the commercial formulation [85]. Similar findings were reported for fenofibrate, a 
traditional example of a hydrophobic API that shows variations in the absorption between fed 
and fasted states. The extent of absorption varies from 30% to 50% and from 60 to 90% in the 
fast-state and the fed state respectively. However, the administration of nanosized fenofibrate has 
led to the absence of food effect (i.e., fed/fasted state variations) in human [32]. 
Nanoparticles have a unique ability of adhesiveness to the biological barrier, such characteristic 
can be further enhanced by adding special excipients in the formulation such as mucoadhesive 
polymers (e.g., carbopol and chitosan) [86]. 
Compared to suspensions of microsized APIs, suspensions of nanosized API formulations 
have been shown to achieve higher levels of systemic exposure (the amount of drug that 
exerts biological action) to in vivo dissolution media, due to their higher surface areas and 
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higher dissolution rates [30]. Such increase is an important step at the preclinical studies 
because it can lead to a considerable reduction in the amount of API needed for 
toxicological studies [41]. Nanosized APIs could also be used in controlled release dosage 
forms. For example, ketoprofen controlled release pellets were studied to combine 
nanosuspensions produced by the nanocrystal technology with modified release technology [87].  
5. Nanosized APIs in pulmonary delivery systems 
Nanoparticles are attractive for API delivery to the lungs and, therefore, they have become a 
subject of a very active research. This is because aerosol formulations containing nanosized APIs 
have many advantages over traditional aerosol formulations [88–91]. 
Nanosized APIs can be suitable for the delivery to the deep lung because of their low-density 
microstructure. Applying nanotechnology to particle engineering to enhance pulmonary drug 
delivery is one of the most attractive advances [92]. Engineering nanosized formulations offers 
the opportunity to control the physicochemical properties of the resultant formulations, i.e., 
producing nanoparticles with predetermined properties [93]. For example, nanosized APIs have 
been engineered in terms of size and shape to avoid the clearance and increase the residence time 
at the site of action [3]. Nanoparticles could be agglomerated in a controlled manner to achieve 
micro-sized particles with both improved aerosolization and dissolution behaviors [94]. For 
instance, micron-sized structures composed of polystyrene, polyacrylate, gelatin or chitosan were 
engineered from nanoparticles to enhance the delivery efficacy of APIs to the lung [91,95–98]. 
Large porous agglomerates with a large geometric diameter but a small aerodynamic diameter 
were also engineered from nanoparticle drug formulations [99–101]. Inhaled nanoparticles 
formulated with polysorbate 80 and poloxamer 407 containing itraconazole proved a better 
physiological efficiency and a reduced required effective dose in comparison to the oral delivery 
[102]. Nanosized API particles were used to coat microsized API particles and thus a reduced 
degree of API-API cohesive forces was achieved [103,104]. Polymeric nanoparticles proved to 
be potential for pulmonary drug delivery [105]. Nanoparticles have a higher likelihood of 
biotransfer into the blood through the pulmonary membrane and, therefore, they may be potential 
for intracellular drug delivery [93]. 
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Drug release from nanoparticles can be altered by manipulating their biodegradation process 
[106]. Therefore, nanoparticles may be advantageous to provide sustained release (i.e., 
increasing the residence time of APIs in the airways), which offers dose frequency reduction and 
better patient compliance [107,108]. Generally, a sustained release of an API to the lung could be 
obtained via the use of mucoadhesive materials such as chitosan, a biodegradable poly-
saccharide. For instance, preparing chitosan surface-modified poly(lactide-co-glycolide) (PLGA) 
nanoparticles resulted in a prolonged release of elcatonin (a protein API) and consequently a 
prolonged reduction in blood calcium levels compared to unmodified PLGA nanoparticles [109]. 
Sodium alginate formulated with chitosan is a natural polymer that has been used to prepare 
prolonged release nanoparticle formulations containing three antitubercular APIs [110]. Surface-
modified PLGA nanoparticles with wheat germ agglutinin (WGG, a bioadhesive lectin) 
demonstrated sustained API release [111]. Also, PLGA nanoparticles containing insulin proved 
considerable sustained physiological efficiency [107]. 
Nanoparticle drug delivery systems are potential to target delivery of small molecules and 
macromolecules to specific cells and organs both in vitro and in vivo [96,106,112]. Nanosized 
systems have been widely used to target specific tumor cells in cancer therapy. Such 
targeted drug delivery is advantageous in terms of reducing the effective dose and side effects 
[111,112]. 
6. Techniques to prepare nanosized APIs 
Methods for preparing nanocrystals can be classified into two main categories (Table 2): bottom-
up techniques, where the molecules are built up, and top-down techniques, in which the crystals 
are commuted. A combination of top-down and bottom-up methods can also be used. Regardless 
of the preparation method, it is very important to understand the exposure/safety profile during 
development in order to administer the nanosized APIs safely in the clinic [36]. 
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Table 2. A summary of some techniques (EPAS, evaporative precipitation into aqueous solution; HGCP, high 
gravity controlled precipitation; HPH, high-pressure homogenization; RESS, rapid expansion in supercritical fluid; 
SAS, supercritical anti-solvent; SFL, spray freezing into liquid) employed in the preparation of nanosized APIs. 
Strategy  Technique Methodology description Examples 
B
o
tto
m
-u
p
 
Antisolvent 
precipitation 
(magnetic stirrer) 
Drug is dissolved in an organic solvent and then it 
is mixed with an antisolvent (usually water). 
 
[101,113] 
Sonoprecipitation Crystallization by ultrasonic waves. [100,113–119] 
HGCP 
Precipitation under high gravity conditions usually 
obtained by using rotating packed bed. 
[67,120–124] 
EPAS 
Drug is dissolved in a low boiling point solvent. 
The solution is then heated above the boiling point 
and then sprayed in an aqueous heated solution 
containing a stabilizer. 
[70] 
RESS 
Drug is solubilized in a supercritical fluid and is 
expanded in a low-pressure area through a nozzle. 
[125,126] 
SAS 
Drug is dissolved in organic solvent, initiating the 
precipitation of solutes by antisolvent effect. 
[65,127,128] 
SFL 
Drug is solubilized in a mixture of 
aqueous/organic solvents with or without stabilizer 
then sprayed in liquid nitrogen, causing immediate 
precipitation. 
[129] 
T
o
p
-d
o
w
n
  
HPH 
Drug particles suspended in a dispersion medium 
are passed several times through a high-pressure 
homogenizer. 
[55,130–139] 
Wet milling 
Drug particles are fed into a solution containing a 
stabilizer. The drug particles are then subjected to 
milling by glass beads. 
[20,33,60,61,82,87,140–
144] 
Salt-assisted milling 
Drug particles are milled in the presence of a salt 
such as NaCl. 
[145,146] 
Co-grinding 
Drug particles are co-grinded with additives such 
as polymers. 
[147–150] 
B
o
tto
m
-u
p
 
fo
llo
w
ed
 b
y
 to
p
-
d
o
w
n
 
Precipitation‒HPH 
Drug particles are precipitated in the presence of 
an antisolvent and then processed by a high-speed 
homogenizer. 
[151,152] 
Spray-drying‒HPH 
Drug particles are spray-dried and then processed 
by a high-speed homogenizer. 
[153] 
Freeze-drying‒HPH 
Drug particles are freeze-dried then processed by a 
high-speed homogenizer. 
[154] 
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6.1. Nanoprecipitation-dependant techniques 
6.1.1. Principle 
In nanoprecipitation, the lipophilic API is dissolved in an organic solvent, and then the resultant 
solution is added to an antisolvent (usually water or water-miscible antisolvent). Four steps are 
involved in this process: 1) chemical reaction (and the subsequent supersaturation), 2) 
nucleation, 3) solute diffusion and 4) particle growth [155]. This process is followed by phase 
separation to remove the organic solvent (e.g., by evaporation) and to isolate the API particles 
formed. 
Supersaturation is obtained very rapidly due to the drowning-out effect of the antisolvent, which 
reduces solute solubility inducing its precipitation. The nucleation and particle growth are both 
dependent on the level of saturation [155]. Nanocrystal preparation methods using this technique 
can be classified according to the mixing type, solvent/antisolvent nature and the process used.  
Micromixing is an important factor that may affect particle size of the product. Uniform 
micromixing may affect the concentration on the particle surface (Ci) as illustrated by Eq. 4. 
  
  
             (Eq. 4), 
where dl/dt is the growth rate, Kg is the solute diffusion constant rate, C is the bulk concentration 
and b has the value between 1 and 3 (b value increases with temperature). Based on Eq. 4, an 
insufficient micromixing will lead to different nucleus growth rates and consequently a wide 
distribution of particle size [156]. The choice of solvent is critical because it may affect the 
physicochemical properties of the nanosized APIs produced [157].  
6.1.2. Advantages 
Nanoprecipitation is a relatively fast, simple and cost-effective technique [86] that is suitable for 
thermolabile compounds, and can produce a high yield of crystalline [79] and/or amorphous 
[158] nanosized APIs. 
6.1.3. Disadvantages 
Nanoprecipitation should be controlled precisely in order to control the size and the size 
distribution of the resultant nanoparticles.  
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Although some of the nanoprecipitation techniques have been successfully scaled up, the process 
of nanoprecipitation is not usually suitable for industrial scale-up [155]. Some of the 
nanoprecipitation equipment, such as those used in high gravity precipitation, are highly 
specialized and not widely available. Nanoprecipitation processes may require the control of 
potential residual solvents in the product. Nanoprecipitation suffers from the requirement of 
solvent recovery and the risk associated with the use of flammable solvents at high reaction 
temperatures. Some nanoprecipitation techniques, such as the hydrosol method, usually produce 
nanosized APIs with a wide distribution of particle size [159]. Additionally, nanoprecipitation 
suffers from batch-to-batch variability due to the rapid precipitation nature of this crystallization 
process. 
6.1.4. Applications 
Nanoprecipitation is involved in many pharmaceutical techniques such as pharmaceutical 
hydrosols [160], flash nanoprecipitation [121], sonoprecipitation [44,162] and high-gravity 
controlled precipitation [121,124,163]. 
6.1.4.1. The pharmaceutical hydrosol method 
The pharmaceutical hydrosol method is a simple and a cost-effective method that has been used 
to produce a wide range of nanosized API particles with enhanced biological absorption, such as 
carotenoids (a mean size of 25 - 250 nm) [160], darodipine (a mean size of 116 nm) [164], 
progesterone (a mean size of 245 nm) [164], cyclosporine A (a mean size of 80 nm) [165], blue 
quinone (a mean size of 210 nm), red methine (a mean size of 310 nm) [166] and itraconazole (a 
mean size of 600 nm) [167]. Hydrosols have also been successfully used to prepare nanosized 
carbamazepine and oxcarbazepine using static mixers [168,169]. 
In brief, the lipophilic API is dissolved in an organic solvent, and subsequently a large amount of 
an antisolvent (usually water) is mixed with a macromolecule (such as gelatin and serum 
albumin [160]) and then added to the organic solvent with rapid mixing to guarantee fast 
nucleation of nanoparticles [170]. The mixing can be achieved by magnetic mixer yet there are 
more sophisticated equipment that could be used for industrial scale production [155]. 
Desolvating agents such as aqueous solutions containing multivalent ions (e.g., Ca
2+
 or SO4) and 
hardening agents (e.g., aldehyde) may be added [171]. Pure insulin nanoparticles were also 
prepared using the pharmaceutical hydrosol method. Insulin was dissolved in a 0.01 N HCl 
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solution, and then it was titrated with a NaOH solution to the isoelectric point before it was 
diluted with deionized water. The subsequent nanoparticles were further agglomerated into 
microparticles by the addition of ethanol and stirring for 36 h at 300 rpm, making them suitable 
for pulmonary API delivery via dry powder inhalers (DPIs) [99]. 
Different stabilizers have been used to prevent the aggregation of the produced nanosized APIs, 
including polymers (e.g., polyvinyl alcohol (PVA), cellulose ethers, chitosan, agar, pectin, and 
gelatin), sugars (e.g., trehalose), and surfactants (e.g., poloxamers, partial fatty acid esters, 
polyoxyethylene fatty alcohol ethers and phospholipids) [167]. It is worth noting that polar 
stabilizers (such as dextra and hydroxyethyl starch) demonstrated a poor performance as 
compared with hydrophobic cellulose ethers. This may be explained as the cellulose ethers are 
more hydrophobic and, therefore, they interact with the surface of hydrophobic APIs better than 
the polar stabilizers, thus they provide a better protection for the APIs against aggregation [167]. 
6.1.4.2. Nanoprecipitation by acid-base reaction 
Nanoprecipitation by acid-base reaction has been used to prepare nanocrystals of itraconazole, a 
poorly soluble compound in an aqueous solution with a pH-dependent solubility (solubility: 1 
ng/mL at a neutral pH and 6 mcg/mL at a pH of 1). For example, Mou et al. [118] prepared 
itraconazole nanocrystals with a mean diameter of 248 nm. In brief, itraconazole was solubilized 
in an acidic aqueous solution containing ethanol. The precipitation process was induced by 
adding the latter solution to a solution of stabilizer in sodium hydroxide.  
6.1.4.3.  Sonoprecipitation 
Sonoprecipitation technique has been used to prepare nanocrystals of several APIs such as 
simvastatin [114], fenofibrate [115], scutellarin [116], felodipine [117] and itraconazole [118] 
(Tables 3 and 4). By controlling the process variables, such as the sonication duration and 
intensity, sonoprecipitation can engineer nanosized APIs with controlled/improved 
physicochemical properties, such as particle size distribution (PSD), solid-state and dissolution 
rate [44,162]. For example, Chow et al. [119] reported that the dissolution rate of nanosized 
acetaminophen has decreased with increasing the concentration of an additive (p-
acetoxyacetanilide) to a specific limit, after which the dissolution rate has increased. Budesonide 
nanoparticles suitable for inhalation were also produced using the sonoprecipitation method 
(Table 3). Budesonide was dissolved in acetone and the resultant solution was injected into water 
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at a flow rate of 1 mL/min under sonication within an ice bath. A combination of hydrophobic 
(cetyl alcohol and span 85), hydrophilic (phospholipid (PL), PVA and polyvinylpyrrolidone 
(PVP)) and amphoteric (lecithin) surfactants were used to stabilize the formulations. Then, L-
leucine was employed to prepare aggregations of the resultant budesonide nanoparticles suitable 
for pulmonary delivery, and with an improved dissolution rate in comparison to the commercial 
budesonide. Rod-shaped sonoprecipitated nanosized APIs showed a superior dissolution 
behaviour in comparison to milled nanocrystals [62,94]. Agglomerates of rod-shaped 
sonoprecipitated nanosized theophylline with a mean size suitable for inhalation (2.47 µm) were 
also prepared [94]. Sonoprecipitation has been used to prepare nanosized systems containing a 
combination of nanoprecipitated APIs. For example, El-Gendy and Berkland [100] prepared 
combinational chemotherapeutic dry powder aerosols via controlled nanoparticle aggregation. In 
the latter study, paclitaxel nanosuspensions were sonoprecipitated using various surfactants. The 
resultant nanosuspensions were then injected into a cisplatin solution to prepare a combination 
therapy of paclitaxel nanoparticles/cisplatin powders, which were agglomerated using L-leucine. 
The dissolution of the nanoparticles was significantly enhanced compared to the as received 
materials (Table 2). Sonoprecipitation usually gives variable yields depending on the operation 
conditions (e.g., ultrasound frequency/intensity, horn tip size, immersion depth, liquid volume, 
and time) [79,173]. 
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Table 3. A summary of some nanosized APIs prepared by several techniques (sonoprecipitation, high gravity controlled precipitation (HGCP), wet-
milling, high-pressure homogenization (HPH), spray-drying and supercritical fluid (SCF) technology) in the presence of several stabilizers (BSA, bovine 
serum albumin; HPC, Hydroxypropyl cellulose; HP‒β‒CD, 2-Hydroxypropyl-β-cyclodextrin; PVA, polyvinyl alcohol; PVP, polyvinylpyrrolidone; 
SDS, sodium dodecyl sulphate; TPGS, D‒α‒tocopherol polyethylene glycol succinate), and their main characteristics. 
Technique API Category Delivery system Route Mean size 
(SD) or size 
range (nm) 
Solid-state Stabilizer Reference 
S
o
n
o
p
rec
ip
ita
tio
n
 
Simvastatin Lipid lowering agent  Nanosuspension  Oral 360 (9)  Partially crystalline Poloxamer 188 [114] 
Fenofibrate Lipid lowering agent Nanosuspension  Oral 460 (20) Crystalline Poloxamer 188 [115] 
Scutellarin Antioxidant  Nanosuspension  Oral 378 (28) Crystalline Polysorbate 80 [116] 
Felodipine 
Antihypertensive 
agent  
Nanosuspension 
Oral 60-410 Partially crystalline PVA or hypromellose [117] 
Felodipine 
Antihypertensive 
agent 
Nanosuspension 
Oral 140  
Crystalline or 
amorphous PVP and SDS [113] 
Itraconazole Antifungal  
Nanosuspension  
Oral 248 (15) 
Crystalline before 
drying and amorphous 
after drying Hypromellose [118] 
Budesonide Corticosteroid 
Powder 
Pulmonary 160-230 Partially crystalline 
Lecithin, cetyl alcohol 
and pluronic F127 [119] 
Paclitaxel Anti-tumor agent  
Powder 
Pulmonary 289-367 Amorphous 
Cetyl alcohol, PVA, 
PVP, and lecithin. [100] 
H
G
C
P
 
Azithromycine Antibiotic Nanosuspension Oral 200 (20) Amorphous Soybean lecithin [120] 
Salbutamol sulfate β2‒adrenergic receptor 
agonist 
Powder Pulmonary 100-500 Crystalline … [67] 
Danazol Corticosteroid Nanosuspension  Oral 100-300 Crystalline … [121] 
Cefuroxime Antibiotic Nanosuspension Oral 300 Amorphous … [122] 
Beclomethasone Corticosteroid Powder Pulmonary 850 Crystalline … [123] 
Cephradine Antibiotic Powder Pulmonary 200-400 Crystalline … [124] 
W
et-m
illin
g
 
Danazol Corticosteroid Nanosuspension Oral 169 Crystalline PVP [82]  
Naproxen NSAID Nanosuspension Oral 270 Crystalline SLS [140] 
Naproxen NSAID Nanosuspension Oral 328-536 Crystalline 1 % HPC and 1.2 % 
arginine 
[60] 
Aprepitant Anti-nausea Nanosuspension Oral 480 ... 4 % HPC and 0.08 % 
SDS 
[20] 
Ketoprofen NSAID Pellets Oral 230-240 ... ... [87] 
Loviride Anti-HIV Powder Oral 567 (25) Partially crystalline Tween 80 and 
poloxamer 188 
[174] 
Cinnarizine Anti-histamine Nanosuspension Oral 366 (12) ... TPGS [61] 
Phenylbutazone NSAID Nanosuspension Oral 498 (10) ... TPGS [61] 
Griseofulvin Antifungal Nanosuspension Oral 256 (1) ... TPGS [61] 
Indomethacin NSAID Nanosuspension Oral 193 (2) ... TPGS [61] 
Mebendazole Anthelmintic Nanosuspension Oral 190 (2) ... TPGS [61] 
Phenytoin Anti-epileptic Nanosuspension Oral 406 (17) ... TPGS [61] 
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Curcumin Flavoring agent Powder … 250 Partially crystalline … [141] 
Cilostazol Phosphodiesterase 
inhibitor 
Nanosuspension … 220 ... HPC and docusate 
sodium 
[33] 
Iitraconazole Antifungal Nanosuspension Oral 310 (130) ... HPC and PVP   [144] 
Nifedipine Antihypertensive Nanosuspension Oral 190 (70) ... HPC and PVP [144] 
Ibuprofen NSAID Nanosuspension Oral 420 (80) ... HPC and PVP [144] 
Prednisolone acetate Corticosteroid Nanosuspension Oral 70 (40) ... HPC and PVP [144] 
Itraconazole Antifungal Nanosuspension Oral 549 (51) Partially crystalline Tween 80 [143]. 
Zn-insulin Antidiabetic Nanosuspension Parenteral 114 Amorphous Pluronic F68 and 
sodium deoxycholate 
[142] 
H
P
H
 
Azithromycin Antibiotic Nanosuspension Oral 400 Amorphous Pluronic F68 [55]  
10-
hydroxycamptothecin 
Anti-cancer Nanosuspension Oral 131 Amorphous Poloxamer 188 [130] 
Omeprazole Proton pump inhibitor Nanosuspension Parenteral <1000  … Poloxamer 188 [132] 
Buparvaquone Anti-parasite Mucoadhesive 
hydrogel 
Oral 600 Amorphous Poloxamer 188 with or 
without lecithin or PVA 
[131] 
Atovaquone Anti-toxoplasmosis Nanosuspension Parenteral 279 (7) … Tween 80 [139] 
Amphotericin B Anti-fungal Nanosuspension Oral 528 … … [138] 
Nimodipine Antihypertensive Nanosuspension Oral 133-858 Mostly crystalline Poloxamer 407 [137] 
Myricetin Antioxidant 
 
Nanosuspension Oral 300-500 Amorphous Soya lecithin, TPGS 
and/or HP‒β‒CD 
[133] 
Revaprazan 
hydrochloride 
Proton pump inhibitor Nanosuspension Oral 562 (16) Partially crystalline Poloxamer 188 [136] 
Itraconazole Antifungal Nanosuspension IV 580 (18) … Poloxamer 188 [134] 
Curcumin Anti-inflammatory Nanosuspension Oral 600 Amorphous … [135] 
Asulacrine Topoisomerase II 
inhibitor 
Nanosuspension Parenteral 133 (20) Crystalline Poloxamer 188 [26] 
S
p
ra
y
-
d
ry
in
g
 
Iitraconazole Anti-fugal  Powder  …  450  Crystalline Poloxamer 188, 
deoxycholate and 
mannitol  
[63]. 
Fenofibrate  Antihyperlipidemic  Powder  Oral  553  Crystalline  SDS, hypromellose and 
mannitol 
[64]  
S
C
F
 tec
h
n
o
lo
g
y
 
Phenytoin Antiepileptic Nanosuspensions Oral 160 Crystalline … [175] 
Prednisolone Corticosteroid Nanosuspensions Oral 230 Crystalline SDS and PEG 4000 [176] 
Apigenin Anti-cancer Powder/capsules Oral 400-800 Crystalline … [177] 
Tetracycline Antibiotic … Oral 125-400 … … [178] 
Griseofulvin Antifungal … Oral 130 Crystalline … [127] 
Ibuprofen NSAID Powder Oral 25-276 Partially crystalline PVP, PVA, SDS or 
BSA 
[125] 
Cyclosporine Immunosuppressant Nanosuspensions Oral/IV 400-700 … Tween 80 [179] 
Paclitaxel Anti-cancer … … 275 Crystalline … [180] 
Theophylline 
 
Anti-asthmatic … Oral 85 Partially crystalline … [181] 
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Table 4. Scanning electron microscopy (SEM) photographs of some nanosized APIs prepared using high gravity 
controlled precipitation (HGCP) in comparison to their parent raw materials. 
API Raw material Nanosized material Reference 
Azithromycine 
  
[120] 
Danazol 
  
[121] 
Beclomethasone  
  
[123] 
Cephradine 
  
[124] 
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6.1.4.4. Nano-coprecipitation 
It is also feasible to produce nanosized APIs by API-excipient nano-coprecipitation. For 
example, nifedipine nanoparticles were prepared by dissolving nifedipine and stearic acid in 
ethanol and then adding the subsequent solution to deionized water, allowing the precipitation of 
nanoparticle colloids exhibiting negative surface charge [101]. Sodium chloride (NaCl) was used 
to disrupt the electrostatic repulsion between the nanoparticles to achieve agglomerated 
nanoparticles of a controlled size and an enhanced dissolution performance. Nano-
coprecipitation has been used to prepare nanosized APIs with different solid-states. For example, 
Lindfors et al. [113] prepared both amorphous and crystalline nanosuspensions of felodipine. 
Amorphous felodipine nanosuspensions were prepared by rapidly injecting felodipine dissolved 
in N, N-dimethylacetamide (DMA)) into an aqueous stabilizer solution (0.2% (w/w) PVP K30 
and 0.25 mM sodium dodecyl sulphate (SDS)) in a vial placed in an ultrasonic bath. Miglitol was 
added to the felodipine API solution at a felodipine:miglitol ratio of 4:1 (w/w) to inhibit Ostwald 
ripening. Crystalline felodipine nanosuspensions were prepared using a same procedure but with 
30 min sonication time and without adding miglitol. The amorphous nanosized felodipine 
nanoparticles demonstrated much higher solubility in comparison to the crystalline nanosized 
felodipine. The stability of the amorphous nanosuspensions was very sensitive to the presence of 
tiny amounts of the crystalline form.  
6.1.4.5. High gravity controlled precipitation 
High gravity controlled precipitation (HGCP) has also been used in nanoprecipitation (Table 2). 
In this method, the solution going through the rotating packed bed (RPB) packing is atomized 
into very fine droplets, threads, and thin films under the high shear field where micromixing take 
place [129]. The HGCP method can be run in two modes: high gravity reactive precipitation 
(HGRP) (where two reactants form nanocrystals under high gravity) and high gravity antisolvent 
precipitation (HGAP) (where a solvent-antisolvent reaction takes place under high gravity). The 
HGRP method, invented by Chen et al., [183], was first used to produce nanocrystals of an 
inorganic compound, i.e., CaCO3. Chen et al. [163] demonstrated the capability of the HGRP 
method to produce nanosized APIs using benzoic acid as a model API. The main factors that 
affect the size of the HGRP engineered nanosized APIs were shown. Particle size decreased with 
increasing bed speed, concentration and volume flow rate of the reactants. Particle size was 
decreased from 600 nm to ~ 50 nm when increasing the bed speed from 15 Hz to 20 Hz. 
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However, no significant decrease in particle size was observed when a bed speed above 20 Hz 
was used. A similar trend was observed regarding the influence of flow rate of the reactants on 
particle size. Finally, increasing the concentration of HCl from 0.1 to 0.5 mol/L has decreased 
the particle size of benzoic acid from 70 nm to 10 nm.  
The HGRP method has been applied to prepare nanosized APIs such as azithromycin [120] and 
salbutamol sulphate [67] (Table 4). The HGRP engineered azithromycin nanocrystals showed a 
mean particle size of 300-500 nm and ~ 90% dissolution rate after 15 min in comparison to a 50 
% dissolution rate obtained from for the raw material [120]. The HGRP engineered salbutamol 
sulphate nanocrystals, prepared by vigorous mixing of an isopropanol solution of salbutamol 
sulphate with sulfuric acid in RPB, demonstrated a mean size between 100 and 500 nm. These 
nanocrystals were further spray-dried to form agglomerates of a mean diameter of 2 µm suitable 
for inhalation via DPIs [67]. The HGRP method is convenient, cost-effective and suitable for the 
industrial production of nanosized APIs. However, a by-product might be produced restraining 
the overall process [129]. 
In contrast to the HGRP method, the HGAP method does not often produce by-products. 
However, the HGAP progress may require a large amount of organic solvents [129]. The HGAP 
method was used to prepared nanosized danazol that demonstrated a mean size of 100-300 nm 
and a dissolution rate of 80 % after 5 min in comparison to 30 % dissolution rate obtained from 
the raw danazol [121]. In brief, danazol was dissolved in ethanol and then mixed with an 
antisolvent (water) by RPB. The HGAP method was also utilized to produce nanosized 
cefuroxime with an enhanced dissolution rate, making it suitable for oral administration [122]. 
Inhalable beclomethasone with a mean size of 850 nm and an enhanced DPI aerosolization 
performance was engineered using HGAP [123].  
Many scientists added further adaptations to the HGCP method. For example, Baxter Inc. 
patented the Nanoedge
®
 that involved precipitation coupled with a high energy process [184]. In 
this method, the API was dissolved in a water-miscible solvent, to which an antisolvent was 
added and then energy (heat and/or mechanical stress) was introduced to the resultant mixture to 
form particles with a mean size between 400 nm and ~ 2 µm. High energy was also used to 
convert the unstable/metastable API forms (e.g., amorphous, semicrystalline or supercooled 
liquid form) to stable crystalline API forms [134]. A combination of HGRP and HGAP methods 
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was used to engineer nanosized cephradine particles with a mean size of 200-400 nm and a fast 
dissolution rate [124]. 
6.2. Milling-dependent techniques 
6.2.1. Wet milling technique: The NanoCrystal® technology 
6.2.1.1. Principle 
Wet milling, or commercially known as the nanocrystal technology, is an aqueous based top-
down milling process in which nanosized APIs (usually smaller than 400 nm) can be obtained by 
demoting microsized APIs into the nanodimensions [185,186]. This attrition process is achieved 
in the presence of surface modifiers or grinding media [140]. Grinding media with a size of ≤ 1 
mm are usually preferred in order to impart less wear to the mill [140]. The process could be 
achieved either with [14] or without [187] high energy input. The high-energy milling is 
regarded as a universal procedure to produce nanocrystals. The API powders, usually in micro-
size, are charged to a milling chamber, which contains milling beads that are moved by either 
electric or magnetic stirrer (Figure 1). 
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Figure 1. A schematic representation of the Media Milling Process, modified from Merisko-
Liversidge et al. [27]. 
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Nanosized APIs may be achieved following ~ 30–120 min milling [188]. The API:stabilizer ratio 
usually ranges between 2:1 and 20:1. A suitable amount of a stabilizer has to be used in each 
formulation, i.e., the use of a high amount of a stabilizer may promote Ostwald ripening, whereas 
the use of a too little amount of a stabilizer may lead to aggregation [27]. Common stabilizers 
used include cellulosic, pluronics, polysorbates and povidones. It is also common to use a 
combination of ionic and non-ionic stabilizers [27]. 
Ghosh et al. [189] studied the process factors that may affect the success of the ball milling in 
the term of particle size-reduction. The rotation speed of the planetary ball mill was shown to be 
the most important factor that affects the particle size of the milled products. For example, the 
mean particle size of a nanosuspension was reduced from 1400 nm to 400 nm when the rotation 
speed of the planetary ball mill was increased from 150 rpm to 400 rpm. George and Ghosh 
[190] studied the effect of material property variables that affect the critical quality attributes 
(CQAs) of the nanosuspensions produced. In order to determine the most suitable candidate API 
for media milling, a correlation between the mechanism of stabilization and API properties was 
established. It was concluded that APIs with high enthalpies and high hydrophobicities, that can 
be stabilized either electrostatically or sterically, would be good candidates for media milling, 
and the choice of a stabilizer is influenced by the hydrophobicity of the API (Figure 2).  
 
Figure 2. The strategy of choosing a suitable stabilizer based on API properties [190].  
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Nakach et al. [191] performed a systematic approach to select the best type/concentration of 
stabilizer during nanoparticle engineering. It was found that SDS and PVP at a ratio of 40:60 
(w:w) and a total concentration of 1.2% w/w lead to nanosuspensions with the best stability 
profiles. 
6.2.1.2. Advantages 
Wet milling technique is a leading method to preparing poorly soluble nanosized APIs with 
narrow PSDs [188]. The process is simple and requires few components, i.e., micronized API 
particles, water, and a stabilizer. The method is versatile and suitable especially for APIs with a 
solubility of less than 200 µg/mL [192].  
High API loads could be achieved, thus this technology has been successfully used in the 
commercial context [193]. The safety of the nanosized APIs produced by wet milling has been 
established, as reviewed elsewhere [194]. For example, wet-milled nanosized UG558 (a poorly 
soluble API) [195], AZ68 (a neurokinin NK receptor antagonist) [196] and paclitaxel [52] have 
all been successfully formulated into injectable dosage form and none of these APIs showed an 
adverse effect during animal studies. Nanosized naproxen produced by wet-milling showed less 
gastric irritation in comparison to conventional oral dosage forms [140]. 
Wet-milled nanosized APIs demonstrated an increased bioavailability (as indicated by an 
increased Cmax, a reduced time to maximum plasma concentration (Tmax) and an increased AUC) 
and a reduced fasted/fed variability [51,82,87,140,195,196]. Some wet-milled nanosized APIs, 
such as 1, 3-dicyclohexylurea, showed similar pharmacokinetics to those observed for a solution 
when studied in rats [197].  
Nanosized APIs processed by wet milling demonstrated a higher physical stability and a reduced 
batch-to-batch variability in comparison to APIs processed by other methods such as 
microfluidic precipitation [198]. Wet milling may provide a suitable platform for targeted 
delivery of insoluble APIs or diagnostic agents [192].  
6.2.1.3. Disadvantages 
Wet milling is a time-consuming process that may require hours to days to reach the required 
nanosize range depending on the API and the mill type [187]. Additionally, solid-state alteration 
(e.g., polymorphic transition or chemical degradation) of the APIs may occur during milling 
[199]. For example, long milling times may induce the formation of amorphous content that 
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raises stability concerns [200–202]. Therefore, nanomilling should be performed under 
controlled temperature conditions, and solid-state and chemical stability analyses should be 
conducted before and after wet milling. The use of milling media containing glass or zirconium 
oxide could cause a trace of contaminants to the milling chamber [203,204], thus cross-linked 
polystyrene beads were suggested as an alternative milling medium [27,41].  
Based on the DLVO theory, nanosized API particles have exceedingly high free energy, 
attributable to their high surface area, and consequently they have a high tendency to 
agglomerate [84]. Ostwald ripening observed in wet-milled nanosized APIs is another potential 
drawback [24], in which an API tends to solubilise in water, and then it is crystallized to large 
particles present in nanosuspension. The latter limitations could be avoided by using a carefully 
selected stabilizer [39]. An ideal stabilizer should prevent the aggregation of the nanosized API 
without negatively affecting its solubility.  
6.2.1.4. Applications 
Wet milling has been extensively used to prepare many nanosized APIs, as summarized in Table 
3. For example, in one study, a fast production of sub-100 nm particles of griseofulvin and 
indomethacin was achieved by an intensified wet stirring media milling using small beads [205]. 
Different stabilizers were used during the preparation of wet-milled nanosized APIs, including 
PVP [82], pluronic derivatives [140,192], PVA [60], vitamin E, polyethylene glycol, d–α–
tocopherol polyethylene glycol succinate (TPGS) [61,206] and sodium lauryl sulphate (SLS) 
[87].  
Six products employing the nanocrystal technology are currently available on the market, i.e., 
Rapamune
®
, Emend
®
, Megace
®
 ES, TriCor
®
 145/48, Invega
®
 and Sustenna
®
 [154].  
In general wet milling is used to produce nanosized APIs with enhanced pharmaceutical 
performance, improved safety profile and improved patient compliance [188] (Table 5). Indeed, 
the dissolution enhancement was the main outcome of several studies [33,87,174,207,208]. Wet 
milling has been used to resolve some safety-related issues of some antitumour APIs, such as 
etoposide and paclitaxel. Additionally, wet milling has enabled formulation scientists to produce 
several injectable products for the first time of some poorly soluble APIs such as piposulfan and 
camptothecin [192]. Wet-milling was successfully employed in the preparation of itraconazole-
adipic acid nanococrystals (in the presence of Tween 80
®
 as a surfactant) with an enhanced 
dissolution rate in comparison to amorphous API delivery systems [143]. The preparation of 
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biologically active nanosized peptide particles has also been feasible using the wet milling 
technology. For example, Zn-insulin nanoparticles with a mean diameter of 150 nm and a narrow 
size distribution were produced in the presence of pluronic F68, SDC and water at a neutral pH 
[142] (Table 5). 
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Table 5. Scanning electron microscopy (SEM) or polarized light microscope (PLM) photographs of some 
nanosized APIs prepared using wet-milling in comparison to their parent raw materials.  
API Raw material Nanosized material Reference 
Loviride  
  
[174] 
Curcumin 
  
[141] 
Zn-insulin 
  
[142] 
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6.2.2. Salt-assisted milling  
Salt-assisted milling with steel balls has been shown as a promising approach to producing 
nanosized APIs [145,146]. The process is similar to that used in wet ball milling except that 
additional excipients such as NaCl are employed in the milling medium to prevent nanoparticles 
from degradation [146]. NaCl has been used because it is hard enough to crush soft organic API 
materials, helps to prevent the API particles from aggregation, a water washable material, 
inexpensive and a ‘generally recognized as safe’ excipient. For example, NaCl has been used as 
a milling assistant to produce stable nanocrystals of fenofibrate, a model lipophilic API 
(log P = 5.24) [209] that is virtually insoluble in water (solubility ~ 0.42 mg/L at 25 ºC) [210]. 
Milling efficiency has been shown to be dependent on the rotation speed, fenofibrate:salt ratio 
and milling time. In another research, sugar has been employed to stabilize a nanodiamond 
powder [145]. 
6.2.3. Co-grinding 
Cogrinding is a simple technique that involves grinding APIs with specific additives [147]. 
Cogrinding with different additives has been extensively used to prepare nanosized APIs with 
enhanced dissolution rates [82,149,211,212]. For example, pranlukast [147], ONO-8713 (a 
specific EP1 antagonist) [148], indomethacin, furosemide and naproxen [147] were cogrinded 
with cyclodextrins as grinding additives to produce nanosized APIs with enhanced stability 
profiles. 
Hydroxypropyl cellulose (HPC) [149] and dextrin [150] were used as cogrinding additives to 
produce nanoparticles under suitable water content conditions. The amount of added water has 
been shown as an important factor that has a considerable influence not only on the size but also 
on the stability of the nanosized API preparation. The absence of water could lead to a lack of 
interaction between indomethacin (as an API) and dextrin (as an additive) leading to nanoparticle 
aggregation [150]. 
6.3. High-pressure homogenization 
6.3.1. Principle 
High-pressure homogenization (HPH) is a milling technique that employs a high pressure as the 
main force to produce nanosized APIs. The API particles are usually suspended in a dispersion 
medium and then passed several times through a high-pressure homogenizer (Table 1). 
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Typically, the applied pressure is increased step-wise from 10% to 100% in order to avoid 
clogging of the narrow homogenization gap. The factors that may affect the nanosuspensions 
when being homogenized include fluid shear, particle collision and cavitation [213]. Two 
equipment have been principally employed to produce nanocrystals using high pressure, the 
Microfluidizer [214] and the piston-gap homogenizer [215]. 
The Microfluidizer is a jet stream technique, in which an API is suspended in a dispersion phase 
(usually water) and then pumped into either Z or Y chamber where collision forces are the main 
attributes by which the size of the API particles is reduced [216,217] (Figure 3). 
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Figure 3. A schematic diagram of the Microfluidizer setup, modified from Jafari et al. [217]. 
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In the piston-gap homogenizer, either aqueous or non-aqueous media could also be used as the 
main dispersion phase [218]. In both cases, API particles are charged into a cylinder and then 
passed through a gap of 25 µm. Although cavitation is considered the main important factor of 
nanocrystal production, the PSD of the resultant nanosized API is dependent on many factors, 
including the pressure applied, the number of homogenization cycles and the toughness of the 
API particle [132]. For example, increasing the homogenization pressure from 500 bar to 
1500 bar has been shown to lead to a decrease of the d90% (particle size at 90% volume 
distribution) of a model drug (RMKP 22) from 7.2 μm to 5.6 μm after five cycles [25].  
The polydispersity index of the prepared particles decreased with increasing the number of 
cycles applied. The number of particles with a mean diameter higher than 5 µm has been shown 
to decrease with increasing the processing time. Furthermore, the properties of the nanoparticles 
prepared are dependent on the API processed. For example, cube-shaped, rod-shaped and needle-
shaped nanosized particles were prepared for RMKP 22, prednisolone and RMKP 23 
respectively, although an identical protocol was applied [25].  
6.3.2. Advantages 
The HPH method has been broadly used to produce functionalized nanosized particles for 
versatile applications in food [219], cosmetics [220] and pharmaceutical [221] industries. The 
HPH has been used to engineer poorly soluble nanosized APIs with enhanced dissolution rates 
[222], excellent uniformities and improved dispersibilities [223]. High API loading SLNs with 
rapid dissolution rates of class II API substances [224] were prepared using the HPH 
method. There are also reports where the amorphous and crystalline forms coexist in SLNs 
made by HPH [225]. 
The HPH method is suitable for the continuous production of nanoparticles on both laboratory 
and industrial scale [226]. It can be also used for the production of both immediate and 
controlled release nanosized pharmaceuticals [227–231]. For example, spherical poly(d,l-lactide-
co-glycolide) (PLGA) nanoparticles (200 – 300 nm) for controlling the release of paclitaxel were 
prepared using the HPH method [223]. Long-term stable budesonide nanoparticles suitable for 
nebulization were also successfully produced [232].  
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6.3.3. Disadvantages 
Many process cycles may be needed to produce nanosized APIs in the desired particle size [25]. 
Additionally, polymorphic form transformation associated with the preparation of nanosized 
APIs using HPH technique could be a challenge. For example, some HPH-processed nanosized 
APIs were shown to be amorphous [55,130] and, therefore, sever concern about their stability is 
justified [29]. In such case, alternative methods may be considered. For example, in one study, 
the ultrasound homogenization method was as appropriate as the HPH method for the 
preparation of SLNs [233]. 
6.3.4. Applications  
The HPH method has been extensively used to enhance the dissolution rate of several poorly 
soluble APIs such as azithromycin [55], 10-hydroxycamptothecin [130], omeprazole [132], 
buparvaquone [131], atovaquone [139], myricetin [133], revaprazan hydrochloride [136] and 
asulacrine [26] (Table 3). The HPH method has been used to prepare nanosized APIs with 
different morphologies. For example, rod-shaped (e.g., nimodipine [137], myricetin [133], 
revaprazan hydrochloride [136] and itraconazole [134]), spherical (e.g., curcumin [135]), and 
irregular-shaped (e.g., asulacrine [26]) nanosized API particles were prepared using the HPH 
method (Table 6). Regardless of particle shape, the decrease in particle size of the nanosized 
APIs has been consistently associated with an enhancement of the dissolution rate of the 
resultant nanosized APIs [226,234]. A combination of high speed homogenization and HPH was 
also used to prepare nanosized tobramycin nanoparticles suitable for DPIs. The high-speed 
homogenization was used as a pre-treatment step for the reduction of particle size [235]. 
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Table 6. Scanning electron microscopy (SEM) or transmission electron microscopy (TEM) 
photographs of some nanosized APIs prepared using high-pressure homogenization (HPH). 
API Raw material Nanosized material Reference 
10-hydroxycamptothecin 
  
[130] 
Myricetin 
  
[133] 
Revaprazan HCl 
  
[136] 
Asulacrine  
  
[26] 
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6.4. Spraying-dependent techniques  
6.4.1. Spray-drying  
6.4.1.1. Principle 
Spray-drying is the transformation of a liquid or a dispersion feed from the liquid state to a 
powdered solid phase by spraying the feed into a hot drying medium [236]. The technique 
involves two main steps: atomization followed by drying [237]. 
The Büchi Nano Spray Dryer B-90, innovated by Li et al (2010), has been used to produce a 
high yield (~ 70% to 90%, w/w) of nanosized APIs. The new modified technology uses a 
vibrating mesh to create droplets in a size range smaller than the traditional spray dryer 
[238,239] (Figure 4). The average size of the nanosized particles produced using this technology 
usually ranges from 500 to 2500 nm. The diameter (d) of a spray-dried nanoparticle can be 
predicted using Eq. 5 [155]. 
    
 
 
 
    (Eq. 5), 
where D is the drop diameter, C is the solution concentration and   is particle density. 
The physicochemical properties of the spray-dried APIs are dependent on several process 
parameters such as the inlet temperature, the chamber’s internal moisture content and the liquid 
feed rate [240]. The spray-dried pharmaceutical material suffers from thermal stress, which could 
significantly affect the material’s critical quality attributes (CQAs) [241].  
Usually, spray-drying produce amorphous dispersion systems of poorly soluble APIs [242]. Such 
systems have the drawback of insufficient stability. Nevertheless, the solid-state of the spray-
dried particles depends on formulation factors (e.g., feed concentration or solvent type) and 
process factors (e.g., drying gas flow rate or solution spray rate) [242], and it ranges from 
completely amorphous, semi-crystalline to crystalline forms [243]. For example, spray-dried 
naproxen showed no amorphous form, whereas spray-dried indomethacin showed different 
forms of different stabilities [241]. 
6.4.1.2. Advantages 
Spray-drying can successfully replace freeze-drying in the manufacturing of nanosized parenteral 
APIs. Spray-drying allows good control of particle’s physicochemical properties due to the 
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ability to change several parameters during the spray-drying process such as temperature, nozzle 
design, etc. Additionally, spray-dried products require shorter processing times in comparison to 
freeze-dried products [244,245]. In contrast to freeze-dried products, spray-dried products are 
typically fine and free-flowing powders [245].  
6.4.1.3. Disadvantages 
One main disadvantage of spray-drying is the cost of settings and maintenance [246]. Complex 
biological molecules, such as proteins, are difficult to spray dry because of their sensitivity to the 
high shear stress during the atomization step, which could destabilize labile materials. The 
amount of shear stress encountered depends on the type of atomizing and the atomizing pressure 
used. In general, spray-drying of proteins has been a challenge because of the absence of specific 
process guidelines, thus often a trial-and-error process is used rather than rational Quality by 
Design principles [247]. Spray-drying mostly generates amorphous products, thus the production 
of stable APIs by spray-drying may be a challenge [248]. The spray-drying method can give 
different yields depending on the conditions applied [241]; nevertheless, a low yield is usually 
associated with the spray-drying process due to the loss of the product on the walls. The 
production of nanoparticles by spray-drying is limited not only by the low separation capacity of 
the cyclone but also by the inadequate forces of liquid atomization [249].  
6.4.1.4. Applications 
Spray-drying is a well-established technique that has been used for a century in different areas 
including food manufacturing, fertilizers, oxide ceramic and pharmaceutical processing [250]. In 
the pharmaceutical industry, spray-drying has been used for the preparation of oral and inhaled 
products, pulmonary delivery of proteins and vaccines, and for the processing of viable 
organisms [251]. Recently, there has been increased attention to the use of spray-drying as a 
particle engineering technique for the size-reduction of APIs [252] (Table 3). The production of 
spray-dried nanosized APIs is one approach to overcome the stability and dissolution rate issues 
associated with spray-dried microsized APIs. For example, Yin et al. [253] used the spray-drying 
method to prepare nanosized crystalline BMS-347070 (a COX-2 inhibitor API) (in the presence 
of pluronic F127) with increased dissolution rate and bioavailability in comparison to the 
micronized BMS-347070. Mizoe et al. [254] utilized 4-fluid nozzle spray drier to produce 
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microparticles containing nanosized pranlukast that showed promising properties for pulmonary, 
oral and parenteral delivery.  
6.4.2. Nanoprecipitation–spray drying 
The continuity and scalability of the spray-drying method to produce nanosized formulations 
were investigated by coupling solvent-antisolvent precipitation with immediate spray-drying 
[64]. For example, Hu et al. [64] coupled nanoprecipitation and spray-drying to prepare 
crystalline nanosized fenofibrate particles with enhanced stability and dissolution rate behaviours 
in comparison to physical mixtures. SDS and hypromellose were used as stabilizers, whereas 
lactose or mannitol was used as resdispersants. 
Nanospray-drying is a convenient method to prepare controlled submicron API delivery vehicles 
useful for pulmonary application, potentially allowing access to the alveolar tissue [105]. A 
combination of nanoprecipitation and spray-drying methods has enabled scientists to develop 
large porous nanoparticles for the delivery of hydrophobic APIs. The so-called ‘Trojan particles’, 
developed by Tsapis et al. [95], could offer the advantages of both nanoparticle systems and 
large porous particle systems in terms of better flow and dissolution rate properties.  
6.4.3. Ionotropic gelation–spray drying 
Chitosan undergoes a gelation reaction when it interacts with a polyions such as sodium 
tripolyphosphate (TPP) [255]. For example, chitosan/TPP nanoparticles were prepared based on 
the ionotropic gelation of chitosan with TPP. In brief, both chitosan and TPP were dissolved in 
water. The nanoparticles were immediately formed upon mixing the TPP solution with chitosan 
solution. Then, an alkaline solution of insulin was mixed with the TPP solution to form insulin-
loaded chitosan/TPP nanoparticles, which were then mixed with mannitol and subsequently 
spray-dried [97]. This method produced biocompatible nanoparticles suitable for pulmonary 
delivery of APIs. For example, this method was used to prepare chitosan nanoparticles that 
showed a compatibility with respiratory epithelial cells [256]. 
6.4.4. Aerosol flow reactor 
The aerosol flow reactor (AFR) is a single step process that can produce nanosized APIs with 
narrow size distributions. The API is dissolved in a volatile biocompatible solvent and then 
atomized into a gas carrier. Nanoparticles are formed while the solvent is evaporated using a 
heated laminar flow tube [257–259]. The size of the resultant nanoparticles is dependent on 
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several process factors, such as the temperature, solution concentration, atomizer design, API 
solubility and API-solvent interaction [260]. For example, Eerikäinen et al [257] studied the 
effect of temperature on the size of the AFR engineered nanosized beclomethasone. No 
significant difference in particle size was observed when the temperature was between 40 and 
120 ºC. However, a significant increase of particle size was observed at temperatures above 120 
ºC, whereas a reduced particle size was obtained at temperatures above 160 ºC. The AFR method 
allows the direct preparation of nanosized APIs in the powder state. For example, nanosized 
powders (mean size of ~ 90 nm) consisting of a poorly soluble corticosteroid (beclomethasone 
dipropionate) and polymeric materials (e.g., Eudragit E 100 or Eudragit L 100) were successfully 
prepared [257]. However, the AFR method may not be suitable for heat labile APIs and the 
yields obtained depend mainly on nozzle design [258]. 
6.4.5. Emulsification–spray drying  
Nanosized API spheres can be produced by simple emulsification, which enhances the 
encapsulation of highly soluble APIs such as proteins, followed by spray-drying. For example, 
Kawashima et al. formulated peptide nanospheres by diffusion of acetone from an organic phase 
containing chlorinated hydrocarbons to an aqueous phase containing nafarelin acetate (API) and 
PLGA. The same research group applied a modified method, in which methanol was replaced by 
chlorinated hydrocarbons in order to improve the encapsulation efficacy of peptide APIs and 
minimize the preparation time of less than 3 h. Nanosphere suspensions, consisting of PLGA, 
acetone, methanol and the API with PVA solution, have been prepared by mixing under agitation 
[107,261]. 
6.4.6. Electrospraying 
Nanosized API formulations can be prepared by spray-drying utilizing an electrohydrodynamic 
force instead of pressurized air stream for atomization [262] (Figure 4). Applying a high electric 
field will lead to an accumulation of electrical charge in the nozzle and eventually a cone-shape 
(‘Tylor cone’) is formed [263,264]. For example, electrospraying has been used to prepare 
nanosized naproxen with a mean diameter of 100 nm using an applied voltage of 2.7 kV [265]. It 
was shown that the redispersability of the nanoformulations is influenced by the voltage applied, 
whereas the particle shape and degree of crystallinity were independent of the electrical field 
applied.
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Figure 4. A schematic diagram of the preparation of the electrospray setup, modified from [252] 
(diagram not down to scale).  
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6.5. Supercritical fluid technology  
6.5.1. Principle 
A supercritical fluid (SCF) is any material at a temperature and pressure above its critical point. 
A SCF has both the solvation ability like liquids and the effusion ability like gasses. SCFs are 
highly compressible and their solvation ability can be controlled by manipulating the temperature 
and/or pressure applied during processing [266]. SCFs are increasingly used to prepare 
nanosized poorly soluble APIs (typically smaller than 300 nm) by controlling the pre-expansion 
temperature and pressure [267,268]. A common method includes the rapid expansions of 
supercritical solutions (RESS) [269], in which the API is dissolved in a SCF that is then 
expanded into a low-pressure chamber through a nozzle. The differences in the pressure between 
the two chambers allow the API to precipitate [269]. This method has been modified by 
dissolving the API in a liquid to which a SCF is added as an antisolvent that causes API 
precipitation of the API [270,271]. Depending on the method of crystallization, SCF technology 
can be classified into three main processes: gas anti-solvent (GAS) [272], aerosol solvent 
extraction system (ASES) process and solution-enhanced dispersion by SCFs (SEDS) [270]. 
6.5.2. Advantages  
SCF technology could offer several distinct characteristics in their application within the 
pharmaceutical area, including micronization and modification of particle physical properties. By 
manipulating the conditions of the process either micro- or nano-particles could be obtained 
[126]. SCF technology is organic solvent free, easy to scale-up, flexible, and offer the 
opportunity to control the size and morphology of the nanosized APIs produced [260,273]. 
Supercritical CO2 offers many advantages over other SCFs, because it is nontoxic, inexpensive, 
innocuous, nonreactive, noninflammable, environmentally friendly, and has a relatively low 
critical point and a moderate critical pressure [270].  
6.5.3. Disadvantages 
Possible denaturing effects of the solvents or the antisolvents used in SCF technology may cause 
some concerns. The SCF processes usually require long production times [155], although some 
recent methods utilize cosolvents to overcome this limitation [175]. The low solubility of most 
polar APIs in CO2 is one main drawback to SCF technology, making it unsuitable for APIs 
showing poor stability in the aqueous phase. To this end, methanol was used as an alternative 
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SCF, in which the solubility of a polar API could be increased [175]. Moreover, concerns about 
the presence of residual co-solvents should be investigated [274]. Furthermore, SCF technologies 
usually produce nanosized API particles with broad size distributions, and contamination with 
microparticles is usually encountered [270]. Finally, nanosuspensions prepared by SCF 
technology may demonstrate short-term stability [260]. 
6.5.4. Applications 
The dissolution rate enhancement of poorly soluble APIs is one of the most important 
applications of SCF [275]. For example, a threefold enhancement of the dissolution rate of 
phenytoin, a poorly soluble antiepileptic API (solubility ~ 80 µmole/L), was obtained from SCF 
engineered nanosized phenytoin. Nanosized prednisolone (mean size of 230 nm), a model API 
with low solubility in both water and CO2, was engineered using SCF technology. Prednisolone 
was dissolved in an organic solvent in the presence a hydrophilic polymer and a surfactant, after 
which the solution was sprayed into a supercritical CO2 [176]. Nanosized apigenin prepared by 
the SCF antisolvent process showed enhanced dissolution profiles at different pH values in 
comparison to parent particles [177]. Other examples include the use of SCF technology to 
enhance the dissolution rate of tetracycline [178], griseofulvin [127], ibuprofen [125], 
cyclosporine [179], paclitaxel [180] and theophylline [181] (Tables 3 and 7). The SCF 
technology has been also used to engineer nanosized APIs with improved stability. For example, 
SCF technology was used to transform an amorphous salbutamol sulphate to a crystalline form to 
improve its stability and aerosolization performance from DPIs [276]. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
45 
 
Table 7. Scanning electron microscopy (SEM) photographs of some nanosized APIs prepared using supercritical 
fluid (SCF) technology in comparison to their parent raw materials. 
API Raw material Nanosized material 
SCF 
technique Reference 
Phenytoin  
  
RESS-SC [175] 
Apigenin 
  
SAS [177] 
Griseofulvin 
  
SAS [127] 
Theophylline 
  
RESS-SC [181] 
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7. Disadvantages of nanosized delivery systems 
Nanosuspensions are thermodynamically metastable dispersions and, therefore, their stability is a 
critical issue [213]. The stabilization of nanosuspensions could be achieved by adding 
surfactants, which could be charged amphiphiles or non-ionic polymers. The charged 
amphiphiles include bile salts (e.g., sodium cholate) and alkyl sulfonates (e.g., SDS, sodium 
dioctylsulfosuccinate and SLS), and they work by electrostatic stabilization, whereas non-ionic 
polymers (e.g., polysorbates, poloxamines and poloxamers) work by a different mechanism. The 
attachment of the hydrophobic domain of non-ionic polymers of the surfactants creates a 
hydrophobic domain to the surface, which provides a surface affinity that inhibits aggregation. 
Another factor is the layer of hydration that is created by attachment of the hydrophobic domain 
to the particle surface. This layer of hydration needs a work to be removed in order for 
aggregation to be feasible and thus aggregation is inhibited. Furthermore, the hydrophilic 
moieties of surfactants prevent aggregation [213,277]. The API leaking and the uneven API 
distribution are commonly encountered problems with nanoparticles prepared by emulsion [257]. 
Particle reduction of APIs into a nanosized range remains challenging due to the aggregation of 
the high surface area nanosized particles [27]. In the context of pulmonary API delivery, such 
aggregation results in a low emitted dose of the nanosized API upon inhalation, poor flow 
properties, and extreme powder handling difficulties [91]. DPIs containing nanoparticle powder 
formulations have a major drawback, which is their aerodynamic diameter being unsuitable for 
good inhalation delivery [278–280]. This leads to a low API delivery efficiency due to a large 
fraction of the inhaled dose being exhaled. The low API loading efficiency and the difficulties 
associated with scaling the process up are also limitations of the nanosized pulmonary delivery 
systems. Additionally, there are few safety concerns related to the long-term inhalation of 
stabilizers used during the preparation of nanocrystals. It is also very important to control the 
residual solvents and cytotoxic excipients [93] and the potential adverse effects of nanoparticles 
on pulmonary structure and function [281]. 
8. Conclusions and outlook 
Different techniques to produce nanosized APIs were reviewed with emphasis on the merits, the 
limitations and the applications related to each method. The existing production technologies of 
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nanosized APIs are mainly classified into bottom-up techniques, top-down techniques, and a 
combination of both.  
Nanoparticle engineering is a promising tool to resolve many current issues associated with 
poorly soluble APIs, such as those related to poor solubility and dissolution rate. Converting 
nanosuspensions into solid dosage forms can solve many problems associated with API 
development such as poor bioavailability. However, the industrial scale production of nanosized 
systems is still a challenge. This is, in part, because most of the technologies that have been 
utilized to enhance the dissolution rate of poorly soluble APIs via the nanosizing route produce 
amorphous systems, which are metastable and possess tremendous challenges during processing, 
making them unfavourable in the pharmaceutical industry. Additionally, serious challenges could 
be associated with the preparation of nanosized APIs, such as separating the nanosized APIs 
from surfactants, low formulation yield, contamination with microsized particles, and those 
related to the ability to re-suspend the nanosized APIs after drying. Therefore, there is an 
increased need for innovative nanosizing technologies that can produce crystalline APIs with 
both high stability profiles and enhanced dissolution rates. The optimization of nanosizing 
processes using Quality by Design methods might open new horizons in the development of 
nanosized pharmaceutical formulations. 
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Highlights 
 
 Nanoparticle engineering is a promising tool to resolve many current issues associated 
with poorly soluble APIs such as those related to poor solubility and dissolution rate. 
 Serious potential challenges are associated with the preparation of nanosized APIs such 
as separating nanosized APIs from surfactants, low formulation yield, contamination with 
microsized particles, and those related to the ability to re-suspend nanosized APIs after 
drying. 
The optimization of nanosizing processes using quality-by-design methods might open new 
horizons in the development of pharmaceutical formulations. 
